HighTower Advisors LLC Sells 12,912 Shares of Prestige Consumer Healthcare Inc. $PBH

HighTower Advisors LLC cut its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 36.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 22,811 shares of the company’s stock after selling 12,912 shares during the quarter. HighTower Advisors LLC’s holdings in Prestige Consumer Healthcare were worth $1,423,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. First Horizon Corp purchased a new stake in Prestige Consumer Healthcare in the third quarter worth $32,000. Geneos Wealth Management Inc. raised its holdings in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter worth about $46,000. First Horizon Advisors Inc. lifted its position in shares of Prestige Consumer Healthcare by 294.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after purchasing an additional 447 shares during the period. Finally, Hantz Financial Services Inc. boosted its stake in shares of Prestige Consumer Healthcare by 373.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after purchasing an additional 538 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Trending Headlines about Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group reported a new purchase of 10,912 PBH shares (~$681,000), signaling fresh institutional buying interest in the stock. Bleakley Investment
• Positive Sentiment: Zacks bumped a few quarterly estimates: Q4 2026 was raised to $1.59 (from $1.54), Q3 2027 to $1.21 (from $1.20) and Q4 2027 to $1.32 (from $1.26) — small upside revisions that suggest pockets of strength in certain quarters.
• Neutral Sentiment: Zacks Research continues to carry a “Hold” rating on PBH even as it updates estimates; the firm’s commentary so far is a recalibration of numbers rather than a rating change. Consensus full‑year EPS referenced by Zacks remains near $4.50 for the current year.
• Negative Sentiment: Zacks pared several near‑term and fiscal forecasts, which is the main driver of downward pressure: Q1 2027 EPS cut to $1.09 (from $1.24), Q1 2028 to $1.14 (from $1.26), Q2 2028 to $1.30 (from $1.33), Q3 2028 to $1.26 (from $1.28), FY2027 to $4.77 (from $4.84) and FY2028 to $5.06 (from $5.19). Those trims signal slower expected earnings growth and likely explain why the stock is underperforming today.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PBH shares. Canaccord Genuity Group decreased their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Jefferies Financial Group reduced their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Hold” and an average target price of $80.60.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares of the company’s stock, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is owned by insiders.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $69.30 on Monday. The company has a 50 day simple moving average of $65.26 and a two-hundred day simple moving average of $63.45. Prestige Consumer Healthcare Inc. has a fifty-two week low of $57.25 and a fifty-two week high of $90.04. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 2.18 and a beta of 0.41. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. During the same quarter in the previous year, the company earned $1.22 EPS. The business’s quarterly revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).